Evidence map›Paper›PMID 33832352›Full record

ArticleCirculation2021

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF.

Pardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, Samvel B Gasparyan, Michael Böhm, Chern-En Chiang, Akshay S Desai, Jonathon Howlett, Masafumi Kitakaze, Mark C Petrie and 11 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03036124. Cited by 33 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03036124 phase3completed

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Ran2017Enrolled4,744Registered outcomes6Posted comparisons6ConditionsChronic Heart Failure With Reduced Ejection Fraction (HFrEF)Armsdapagliflozin, Placebo
Open the trial in the graph
NCT05580510 phase2 / phase3unknown statusstarted 2023, after this paper: background citation

"An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease"

Ran2023Enrolled160Registered outcomes9Posted comparisons0ConditionsCongenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection FractionArmsEmpagliflozin 10 MG OD, Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
PMID 33447845PMID 30415601PMID 30520545PMID 32865377PMID 33030857PMID 33186500PMID 33960724PMID 34447992PMID 26787434PMID 26787728other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Atherosclerotic features in patients with heart failure.Archives of medical science : AMS · 2025
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Pardeep S Jhund *BHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (P.S.J., K.F.D., M.C.P., J.J.V.M.).
Piotr Ponikowski *Center for Heart Diseases, University Hospital, Wroclaw Medical University, Poland (P.P.).
Kieran F DochertyBHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (P.S.J., K.F.D., M.C.P., J.J.V.M.).
Samvel B GasparyanLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (S.B.G., O.B., A.-M.L., M.S.).
Michael BöhmThe Department of Medicine, Saarland University Hospital, Homburg-Saar, Germany (M.B.).
Chern-En ChiangDivision of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan (C.-E.C.).
Akshay S DesaiDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.S.D., S.D.S.).
Jonathon HowlettCumming School of Medicine and Libin Cardiovascular Institute, University of Calgary, Alberta, Canada (J.H.).
Masafumi KitakazeCardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan (M.K.).
Mark C PetrieBHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (P.S.J., K.F.D., M.C.P., J.J.V.M.).
Subodh VermaDivision of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Canada (S.V.).
Olof BengtssonLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (S.B.G., O.B., A.-M.L., M.S.).
Anna-Maria LangkildeLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (S.B.G., O.B., A.-M.L., M.S.).
Mikaela SjöstrandLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (S.B.G., O.B., A.-M.L., M.S.).
Silvio E InzucchiSection of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.).
Lars KøberDepartment of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (L.K.).
Mikhail N KosiborodSaint Luke's Mid America Heart Institute, University of Missouri, Kansas City (M.N.K.).
Felipe A MartinezUniversidad Nacional de Córdoba, Argentina (F.A.M.).
Marc S SabatineTIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (M.S.S.).
Scott D SolomonDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.S.D., S.D.S.).
John J V McMurrayBHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (P.S.J., K.F.D., M.C.P., J.J.V.M.).

Funding

Yale Diabetes Research CenterP30DK045735 · YALE UNIVERSITY · 1993 to 2025
$10.2M
British Heart Foundation RE/18/6/34217NIDDK NIH HHS P30 DK045735
6 · The paper itself

Abstract

backgroundPatients with heart failure (HF) and reduced ejection fraction will experience multiple hospitalizations for heart failure during the course of their disease. We assessed the efficacy of dapagliflozin on reducing the rate of total (ie, first and repeat) hospitalizations for heart failure in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure).

methodsThe total number of HF hospitalizations and cardiovascular deaths was examined by using the proportional-rates approach of Lei-Wei-Yang-Ying and a joint frailty model for each of recurrent HF hospitalizations and time to cardiovascular death. Variables associated with the risk of recurrent hospitalizations were explored in a multivariable Lei-Wei-Yang-Ying model.

resultsOf 2371 participants randomly assigned to placebo, 318 experienced 469 hospitalizations for HF; of 2373 assigned to dapagliflozin, 230 patients experienced 340 admissions. In a multivariable model, factors associated with a higher risk of recurrent HF hospitalizations included higher heart rate, higher N-terminal pro-B-type natriuretic peptide, and New York Heart Association class. In the Lei-Wei-Yang-Ying model, the rate ratio for the effect of dapagliflozin on recurrent HF hospitalizations or cardiovascular death was 0.75 (95% CI, 0.65-0.88),

conclusionsDapagliflozin reduced the risk of total (first and repeat) HF hospitalizations and cardiovascular death. Time-to-first event analysis underestimated the benefit of dapagliflozin in HF and reduced ejection fraction. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.

Indexed as

AgedBenzhydryl CompoundsFemaleGlucosidesHeart FailureHospitalizationHumansMaleSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triolheart failurerecurrencesodium-glucose transporter 2 inhibitors

Identifiers

PMID33832352
PMCPMC8126492

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.